Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Cash & Equivalents (2017 - 2025)

Serina Therapeutics (SER) has disclosed Cash & Equivalents for 9 consecutive years, with $3.1 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents fell 16.78% to $3.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.1 million through Dec 2025, down 16.78% year-over-year, with the annual reading at $3.1 million for FY2025, 16.78% down from the prior year.
  • Cash & Equivalents hit $3.1 million in Q4 2025 for Serina Therapeutics, down from $8.6 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $8.7 million in Q1 2024 to a low of $261000.0 in Q2 2023.
  • Historically, Cash & Equivalents has averaged $2.9 million across 5 years, with a median of $795000.0 in 2021.
  • Biggest five-year swings in Cash & Equivalents: tumbled 62.82% in 2023 and later soared 3007.14% in 2024.
  • Year by year, Cash & Equivalents stood at $584000.0 in 2021, then increased by 2.74% to $600000.0 in 2022, then skyrocketed by 1169.83% to $7.6 million in 2023, then plummeted by 51.8% to $3.7 million in 2024, then dropped by 16.78% to $3.1 million in 2025.
  • Business Quant data shows Cash & Equivalents for SER at $3.1 million in Q4 2025, $8.6 million in Q3 2025, and $6.0 million in Q2 2025.